Dr. Myassar Zarif, MD

Dr. Zarif practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Dr. Zarif's NPI, 1023082914, was assigned on February 15, 2006. Dr. Zarif graduated from University of Tichreen Faculty of Medicine in 1988. Dr. Zarif holds New York license 231692.

Dr. Zarif's primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Dr. Zarif's primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. Dr. Zarif is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Zarif to 2 more hospitals, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zarif practices, 6 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Zarif's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Zarif is licensed in New York.

CMS data shows 4,805 Medicare services from Dr. Zarif across 19 procedure codes in 2024, for 839 Medicare patients. Medicare paid $153,580 for them.

CMS counts 839 Medicare patients who saw Dr. Zarif in 2024. The largest group is 65 to 74, with 306 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 23% are also on Medicaid. Their average risk score is 1.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zarif's median patient age at 56, with 69% women.

In 2024, Dr. Zarif wrote 4,329 Medicare Part D claims for 531 patients. 87% of them were for generic drugs. CMS names the drug for 3,994 of them, across 74 drugs with 11 or more claims each, at $2,966,063 in total drug cost. In 2023, CMS named 4,479 claims across 79 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Zarif for performance year 2024, reported as part of a group. Dr. Zarif accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zarif as offering telehealth.

Dmand AI links 26 papers to Dr. Zarif, published from 2017 to 2025. 2022 was the busiest year, with 7. The most frequent topics are Multiple Sclerosis, Cognition and Cognitive Dysfunction. Dr. Zarif has published most often in Mult Scler Relat Disord. Dr. Zarif's most frequent co-authors are Mark Gudesblatt, MD, Robert Charles Sergott, MD and Edward Nelson Ofori, DO.

Dmand AI links Dr. Zarif to 1 clinical trial. Conditions studied include Amyotrophic Lateral Sclerosis and TDP-43 Proteinopathies.

CMS Open Payments shows 1,729 general payments to Dr. Zarif from 65 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 71% of the total. Biogen, Inc. paid the most, $213,016. It also lists 5 research payments totaling $979 in 2017.

Dr. Zarif graduated from University of Tichreen Faculty of Medicine in 1988.